GlassScriptPhysician profile
John Paul Gomez
NPI 1811958366
$1,766.70
in general payments reported to CMS, 2019-2025
14 companies · $465 in 2025
The $465 reported for 2025 was more than what 75% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.40 · 2022: $133 · 2023: $448 · 2024: $709 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,621.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $381.40 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $273.11 | 2023-2025 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $247.36 | 2023-2025 | Caplyta |
| Alkermes, INC. | $166.55 | 2020-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $164.36 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $140.58 | 2025 | Cobenfy |
| Lundbeck LLC | $124.56 | 2023-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $114.33 | 2024-2025 | Ingrezza |
| Abbvie INC. | $68.83 | 2023-2024 | |
| Indivior INC. | $26.78 | 2024 | Sublocade |
| Vanda Pharmaceuticals INC. | $18.80 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $15.90 | 2024 | Trintellix |
| Braeburn INC. | $15.63 | 2024 | Brixadi |
| Brainsway USA INC | $8.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Paul Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.